CompletedNCT07038876
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
Researchers compared ML-007C-MA QD, ML-007C-MA BID and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Medication studyAges 18–64United States
Understand this study
What did researchers investigate?
Researchers compared ML-007C-MA QD, ML-007C-MA BID and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
- Listed locations
- Little Rock, United States · Bellflower, United States and 22 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: June 27, 2025
- Recruitment status
- Completed
- Enrollment listed in the registry
- 307
- Sponsor
- MapLight Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT07038876
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Orally Administered ML-007C-MA in Inpatient Adult Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis
Recruitment & locations
CompletedLittle Rock · Bellflower · Culver City
21 more locations
- Garden Grove
- Lemon Grove
- Los Angeles
- Montclair
- Orange
- Riverside
- San Diego
- Sherman Oaks
- Torrance
- Hollywood
- Miami Lakes
- West Palm Beach
- Atlanta
- Decatur
- Chicago
- Marlton
- Staten Island
- North Canton
- Austin
- DeSoto
- Richardson
Questions about this study
What did researchers investigate?
Researchers compared ML-007C-MA QD, ML-007C-MA BID and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.
Who is behind this study?
The study sponsor is MapLight Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Placebo, ML-007C-MA BID and ML-007C-MA QD.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 64 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia